Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience

References

• Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007;18(Suppl. 1):i3–i8.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410–451.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, . Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells. Cancer Res 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, . Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347–7356.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, . Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155–167.
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimet V, . Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618–621.
   PubMed Web of Science ®Google Scholar
• Noonan KA, Ferguson A, Huff CA, . The immunomodulatory role of lenalidomide on Prevnar® responses in patients with relapsed multiple meyloma: a comprehensive analysis of the immune response. Blood 2008;112(Suppl. 1): Abstract 2772.
   Google Scholar
• Wu L, Adams M, Carter T, . Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Baz R, Dimopoulos M, Richardson P, . Lenalidomide-based therapy leads to improvement of humoral immune system in relapsed or refractory multiple myeloma patients who respond to the therapy. Hematologica 2009;94(Suppl. 2): Abstract 0395.
   Google Scholar
• Richardson PG, Schlossman RL, Weller E, . Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–3067.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, . A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Richardson P, Jagannath S, Hussein M, . Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772–778.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, . Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Ishak J, Dimopoulos MA, Weber D, . Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood 2008;111(Suppl. 1): Abstract 3708.
   Google Scholar
• San Miguel JF, Dimopoulos MA, Stadtmauer EA, . Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:38–43.
   PubMed Web of Science ®Google Scholar
• Alegre A, Aguado B, Giraldo P, . Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. Int J Hematol 2011;93:351–360.
   PubMed Web of Science ®Google Scholar
• Delforge M, Facon T, Bravo ML, . Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy. Blood 2009;114(Suppl. 1): Abstract 3873.
   Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, . Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749–760.
   PubMed Web of Science ®Google Scholar
• Yong K, Alegre AA, Browne P, . A multicenter, single-arm, open-label safety and quality of life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma. Haematologica 2010;95(Suppl. 2): Abstract 0944.
   Google Scholar
• Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, . Safety, efficacy, and quality-of-life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma: the Spanish experience. Blood 2010;116(Suppl. 1): Abstract 3045.
   Google Scholar
• Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC—the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38(Suppl. 4):S125–S133.
   PubMed Web of Science ®Google Scholar
• King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555–567.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisløff F, . An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670–1678.
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, v3.0 [internet]. Available from: http://http://www.eortc.be/services/doc/ctc/ctcaev3.pdf
   Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M, . Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738–1744.
   PubMed Web of Science ®Google Scholar
• Lonial S, Baz R, Swern AS, . Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009;114(Suppl. 1): Abstract 2879.
   Google Scholar
• Palumbo AP, Delforge M, Catalano J, . Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. J Clin Oncol 2011;29(Suppl.): Abstract 8007.
   Google Scholar
• Dimopoulos MA, Delforge M, Hájek R, . Lenalidomide plus melphalan and prednisone followed by lenalidomide maintenance provides favourable efficacy and health-related quality-of-life in newly diagnosed multiple myeloma patients =65 years. Haematologica 2011; 96(Suppl. 2): Abstract 0880.
   Google Scholar
• Dubois D, Dhawan R, van de Velde H, . Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 2006;24:976–982.
   PubMed Web of Science ®Google Scholar
• Delforge M, De Samblanx H, Demuynck H, . International observational study on bortezomib (VELCADE) in relapsed multiple myeloma: preliminary efficacy and quality of life (QoL) results from the Belgian population. Blood 2009;114(Suppl. 1): Abstract 4523.
   Google Scholar
• Lee SJ, Richardson PG, Sonneveld P, . Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008;143:511–519.
   PubMed Web of Science ®Google Scholar